GenScript – the life-sciences research tools and services provider – and Avectas, a cell engineering technology company, are partnering to develop an improved non-viral cell therapy manufacturing process.
The two companies are focusing on new methods for developing cell therapies that offer an improved safety profile over viral and non-viral vector techniques.
By combining Avectas’ cell engineering technology and with GenScript’s specialism in synthetic long oligo production, the partnership aims to demonstrate a novel and efficient solution for cell therapy manufacturing and to improve editing efficiency and cell viability over traditional delivery methods.
